Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869759 | 0.86 | MAPT (0.57) | SMN1; SMN2MEN1KMT2AKDM4ELMNA | |
| SCHEMBL14810701 | 0.83 | LMNA (0.57) | KDM4ELMNATRPV1 | |
| SCHEMBL12291584 | 0.82 | TRPV1 (0.50) | SMN1; SMN2MEN1KMT2AKDM4ELMNA | |
| SCHEMBL23582389 | 0.80 | TRPV1 (0.48) | SMN1; SMN2MEN1KMT2ATRPV1F10 | |
| SCHEMBL2635998 | 0.80 | TRPV1 (0.43) | SMN1; SMN2MEN1KMT2AKDM4ELMNA | |
| SCHEMBL4098087 | 0.80 | MEN1 (0.66) | SMN1; SMN2MEN1KMT2AKDM4ELMNA | |
| SCHEMBL4334757 | 0.80 | TRPV1 (0.51) | MEN1KMT2ATRPV1 | |
| SCHEMBL14811590 | 0.80 | TP53 (0.66) | MEN1KMT2AKDM4ELMNATRPV1 | |
| SCHEMBL27705241 | 0.79 | TRPV1 (0.49) | TRPV1 | |
| SCHEMBL20507602 | 0.79 | TRPV1 (0.49) | SMN1; SMN2MEN1KMT2ATRPV1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709723-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233544-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20090221611-A1 | Fused Triazole Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-09-03 | — | — | US | disclosed |
| EP-1817284-A4 | CYCLOALKYL PIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080153851-A1 | Cycloalkyl Piperidine Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-06-26 | — | — | US | disclosed |
| US-20080076783-A1 | Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists | MERCK & CO., INC. (US) | 2008-03-27 | — | — | US | disclosed |
| CN-101061096-A | Cycloalkyl keto piperidine tachykinin receptor antagonists | MERCK & CO INC (US) | 2007-10-24 | — | — | CN | disclosed |
| EP-1817284-A2 | CYCLOALKYL PIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006057977-A2 | CYCLOALKYL PIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153851-A1 | Cycloalkyl Piperidine Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | SMN1; SMN2 3609/4885MEN1 2409/4885KMT2A 1946/4885 |
| US-20080076783-A1 | Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | SMN1; SMN2 3747/4885MEN1 2841/4885KMT2A 1673/4885 |
| US-20090221611-A1 | Fused Triazole Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | SMN1; SMN2 4291/4885MEN1 1806/4885KMT2A 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.